Clinical trials: Metastasis
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Head and Neck Squamous Cell Carcinoma
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of…
- Trial name
- NCT03650764
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Head and Neck Squamous Cell Carcinoma
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC).
- Trial name
- NCT03655444
- Testing
- Abemaciclib, Nivolumab, Tumor biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back.
- Trial name
- NCT01198028
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumors
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
- Trial name
- NCT00756509
- Testing
- Nilotinib
- Where
- 10 sites in Finland, France and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable…
- Trial name
- COMBI-i (NCT02967692)
- Testing
- Spartalizumab, Dabrafenib, Trametinib
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 568 people
- Sponsor
- Novartis Pharmaceuticals
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Drugs used in chemotherapy, such as docetaxel and flavopiridol, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00331682
- Testing
- alvocidib, docetaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as defined…
- Trial name
- AZENT (NCT02841579)
- Testing
- Osimertinib
- Where
- 7 sites in Spain
- Volunteers
- 22 people
- Sponsor
- MedSIR
Melanoma Metastatic
Interleukin-2 in Metastatic Melanoma
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
- Trial name
- NCT01702896
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Western Regional Medical Center
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04828486
- Testing
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Neoplasm Metastasis
Stem Cell Transplantation for Metastatic Solid Tumors
The goal of this research study is to identify other types of cancer (malignant neoplasms) that may be treatable with stem cell transplantation (allogenic peripheral blood stem cell transplantation.
- Trial name
- NCT00001880
- Testing
- methotrexate, Cyclosporin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
Epilepsy
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
The purpose of this study is to evaluate the efficacy and safety of zonisamide for anti-epilepsy drugs (AEDs) treated subjects with refractory simple partial, complex partial or partial with secondary generalized seizures.
- Trial name
- NCT00292461
- Testing
- Zonisamide, Lamotrigine
- Where
- 8 sites in China
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer
Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
The purpose of this study is to investigate the safety and efficacy of different doses and schedules of AZD5363, when in combination with paclitaxel, in treatment of patients with advanced or metastatic breast cancer.
- Trial name
- BEECH (NCT01625286)
- Testing
- AZD5363 when combined with weekly paclitaxel., AZD5363when combined with weekly paclitaxel.
- Where
- 41 sites in Bulgaria, Canada and 9 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.